Glenmark Pharmaceuticals share price fell over 3 percent to Rs 516.45 on November 16 after foreign broking house Morgan Stanley kept “underweight” rating on the stock with the target at Rs 554.
The core business should grow in the low to mid-teens and margin should be stable, however, cash conversion and specialty monetisation are the key value drivers, it said.
Glenmark Pharmaceuticals has been listed in the Dow Jones Sustainability Index (DJSI) under the category of emerging markets for the fourth consecutive year, the company said in a release on November 16.
Inclusion in this list is considered highly prestigious by global investors, financial analysts and other stakeholders and serves as a benchmark for investors who integrate sustainability considerations into their portfolios, it added.
News Source:- Moneycontrol